Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Inhaled Nezulcitinib with Supplemental Oxygen
NCT05091723Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Oct 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nezulcitinib in acute lung injury (ALI) and coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Theravance Biopharma, Inc. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity at 48 hours, Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration at 48 hours and 1 more. Started Oct 2021; status: completed.
02
Drugs
nezulcitinib
03
Conditions
acute lung injury (ALI)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05091723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05091723.